Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Bilthoven – page 95

1 718 clinical trials in Bilthoven, The Netherlands across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Bilthoven at a glance
1 718
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 718 trials in Bilthoven

Open in trial search

Chronic lymphocytic leukaemia

Not recruiting

Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Breast cancer+1

Not recruiting

Study of Tucatinib and Ado-Trastuzumab Emtansine for Patients with Advanced HER2+ Breast Cancer

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tucatinib
  • Sponsor:Seagen Inc.

Acute myeloid leukaemia

Not recruiting

Study on the Safety and Effectiveness of Ivosidenib or Enasidenib with Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia with IDH1 or IDH2 Mutations

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Celgene Corp.

Prostate cancer

Not recruiting

Study on Enzalutamide and Leuprorelin Acetate for Men with High-Risk Nonmetastatic Prostate Cancer After Treatment

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Medivation Inc.

Neoplasm

Not recruiting

Study on Repotrectinib for Patients with Advanced Solid Tumors with ALK, ROS1, or NTRK1-3 Gene Changes

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Repotrectinib
  • Sponsor:Turning Point Therapeutics Inc.

Multiple sclerosis relapse

Not recruiting

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Dementia Alzheimer's type

Not recruiting

Study on Lecanemab and Drug Combination for Patients with Early Onset Alzheimer's Disease Due to Genetic Mutation

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:E2814
  • Sponsor:Washington University School Of Medicine

Myasthenia gravis

Not recruiting

Study on the Safety and Tolerability of DNTH103 for Adults with Generalized Myasthenia Gravis

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Hormone-dependent prostate cancer

Not recruiting

Study on Lutetium-177-PSMA and 18F-PSMA-1007 for Patients with Oligo-metastatic Hormone Sensitive Prostate Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:18F-Psma-1007
  • Sponsor:Stichting Radboud University Medical Center

Thalassaemia

Not recruiting

Study on the Effectiveness and Safety of Mitapivat for Patients with Non-Transfusion-Dependent Alpha or Beta Thalassemia

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Chronic hepatitis B

Not recruiting

Study on the Safety and Effectiveness of Terbinafine for Patients with Chronic Hepatitis B

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Terbinafine
  • Sponsor:Amsterdam UMC Stichting

Embolism venous

Not recruiting

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Anthos Therapeutics Inc.

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Bilthoven

What the registry says about research in the country

01 Infectious Disease Prevention

Research focusing on optimizing vaccine effectiveness against multiple infectious diseases, including studies on meningococcal disease and influenza in different age groups.

  • Meningococcal Disease Prevention
  • Influenza Vaccination Timing
  • Early Measles Protection

Novel approaches include investigating optimal vaccination timing and early immunization strategies for enhanced protection.

02 Oncology Research

Advanced studies in breast cancer treatment, examining innovative therapeutic combinations for hormone receptor-positive cases.

  • Hormone Receptor Positive Breast Cancer
  • CDK 4/6 Inhibition Therapy
  • Sequential Treatment Strategies

Investigations focus on optimizing treatment sequences to improve progression-free survival rates.

03 Surgical Interventions

Clinical research examining surgical treatments combined with antibiotic therapy for improved patient outcomes.

  • Perianal Abscess Management
  • Combined Treatment Approaches
  • Fistula Prevention

Studies aim to enhance surgical outcomes through innovative combination therapies.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.